ArticleCell & bioscience2025
USP43 promotes cerebral ischemia-reperfusion injury via activation of TAK1.
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deubiquitinase USP43 exacerbates myocardial ischemia-reperfusion injury by stabilizing ASK1 and activating the JNK/P38 MAPK pathway.Basic research in cardiology · 2026Article
- The role of USP19 in human diseases: from molecular function to clinical relevance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuroinflammation and apoptosis are important processes of cerebral ischemia-reperfusion injury. USP43 has been shown to play an important role in a variety of cancers, but its function in the field of neuroscience is unclear.
resultsWe used an ischemia-reperfusion model of transient embolization of the middle cerebral artery in mice and found that USP43 protein expression was elevated in mice after ischemia-reperfusion injury. Usp43 knockout reduced cerebral infarct volume, inflammatory response, and cell apoptosis, compared to control mice. In vitro, we used an oxygen-glucose-deprived primary neuronal model of rat cortex. Compared with the control group, the Usp43 knockdown group had better cell activity, and the inflammatory response and apoptosis were reduced. Cells in the Usp43 overexpression group exhibited the opposite performance. Mechanistically, we found that USP43 directly interacts with TAK1 by exerting its function as a deubiquitinating enzyme, removing the K48 chain ubiquitination of TAK1 and activating the TAK1-JNK/p38 signaling pathway. Inhibition of USP43 enzyme activity or the use of TAK1 inhibitors can reverse the inflammatory response and neuronal apoptosis induced by USP43 overexpression.
conclusionsThese results suggest that USP43 promotes I-R damage by activating TAK1 and its downstream signaling pathways. Inhibition of USP43 may be a potential treatment modality for acute stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.